Welcome to our dedicated page for Mangoceuticals SEC filings (Ticker: MGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mangoceuticals, Inc. (MGRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Mangoceuticals describes itself as a Texas corporation whose common stock trades on the Nasdaq Capital Market, and its Form 8-K filings and related documents offer detailed insight into material agreements, financings, and corporate events.
Recent Mangoceuticals filings include Form 8-K reports on private placements of common stock, registered direct offerings and concurrent private placements of warrants, conversions of preferred stock and convertible notes into common stock, and warrant exercises. The company has also filed 8-Ks describing a lease agreement for office space in Dallas, Texas, a separation agreement with a former chief operating officer, and the resignation of a president and director. Other filings outline amendments to promissory notes, issuance of warrants, and the use of an equity line of credit arrangement.
Mangoceuticals’ SEC reports also document its entry into, and subsequent mutual rescission of, a Master Distribution Agreement for exclusive licensing and distribution rights to the nutraceutical Diabetinol in the United States and Canada. Additional 8-Ks reference company press releases about topics such as GLP-1–related programs and other corporate announcements, which are incorporated by reference as exhibits.
On this page, you can review Mangoceuticals’ 8-K filings and other available forms to understand how the company structures financings, manages key agreements, and reports significant events. AI-powered summaries on Stock Titan help explain the main points of lengthy documents, highlight important terms such as conversion prices or warrant conditions, and point out sections related to capital structure and obligations. Real-time updates from EDGAR, along with access to historical filings, allow investors and researchers to monitor MGRX’s regulatory history, governance changes, and transaction activity in a single, organized view.
Mangoceuticals has received a Notice of Effectiveness from the SEC for their Form S-3 registration statement, effective as of June 24, 2025, at 4:00 P.M. The Form S-3 (File Number: 333-288039) is a shelf registration statement that allows the company to offer and sell securities to the public.
A Form S-3 filing indicates that Mangoceuticals meets certain eligibility requirements, including being current with SEC reporting obligations. This registration enables the company to access capital markets more efficiently by allowing them to register securities for future public offerings. The effectiveness notice means the company can now proceed with securities offerings under this registration statement.
Filing highlight: Mangoceuticals, Inc. (CIK 0001938046; symbol MGRX) has received a formal Notice of Effectiveness from the U.S. Securities and Exchange Commission.
The SEC declared the company’s Form S-1 registration statement (File No. 333-287689) effective at 5:00 p.m. on June 18, 2025. This notice confirms that the registration statement has completed the Commission’s review and is now operative.
No further details—such as the size, terms, or purpose of the registered securities—were disclosed in the notice.